Stryker completes acquisition of NICO Corporation, expanding minimally invasive solutions for brain tumor removal and stroke care
Stryker (NYSE: SYK) has completed the acquisition of NICO , a privately held company specializing in minimally invasive surgery for tumor and intracerebral hemorrhage (ICH) procedures. This acquisition strengthens Stryker's position in neurotechnology, particularly in tumor and stroke care. ICH, the deadliest form of stroke, affects over 3.4 million people annually worldwide, with a 30-day mortality rate of 40-50%.
NICO's BrainPath® and Myriad® products offer improved functional outcomes for ICH treatment compared to standard medical management. Andy Pierce, group president of MedSurg and Neurotechnology at Stryker, stated that this strategic addition will enable the company to deliver differentiated, minimally invasive approaches to drive meaningful outcomes and improve patients' lives globally.
Stryker (NYSE: SYK) ha completato l'acquisizione di NICO, una società privata specializzata nella chirurgia minimamente invasiva per tumori e procedure di emorragia intracerebrale (ICH). Questa acquisizione rafforza la posizione di Stryker nella neurotecnologia, in particolare nella cura di tumori e ictus. L'ICH, la forma più letale di ictus, colpisce oltre 3,4 milioni di persone all'anno in tutto il mondo, con un tasso di mortalità a 30 giorni del 40-50%.
I prodotti BrainPath® e Myriad® di NICO offrono risultati funzionali migliorati per il trattamento dell'ICH rispetto alla gestione medica standard. Andy Pierce, presidente del gruppo MedSurg e Neurotecnologia di Stryker, ha dichiarato che questa aggiunta strategica consentirà all'azienda di fornire approcci differenziati e minimamente invasivi per ottenere risultati significativi e migliorare la vita dei pazienti a livello globale.
Stryker (NYSE: SYK) ha completado la adquisición de NICO, una empresa privada especializada en cirugía mínimamente invasiva para tumores y procedimientos de hemorragia intracerebral (ICH). Esta adquisición fortalece la posición de Stryker en neurotecnología, particularmente en el cuidado de tumores y accidentes cerebrovasculares. La ICH, la forma más mortal de accidente cerebrovascular, afecta a más de 3.4 millones de personas anualmente en todo el mundo, con una tasa de mortalidad del 40-50% a los 30 días.
Los productos BrainPath® y Myriad® de NICO ofrecen mejores resultados funcionales para el tratamiento de la ICH en comparación con la gestión médica estándar. Andy Pierce, presidente del grupo MedSurg y Neurotecnología en Stryker, declaró que esta adición estratégica permitirá a la empresa ofrecer enfoques diferenciados y mínimamente invasivos para impulsar resultados significativos y mejorar la vida de los pacientes a nivel global.
Stryker (NYSE: SYK)는 NICO를 인수 완료했습니다. NICO는 종양 및 뇌내 출혈 (ICH) 수술을 위한 최소 침습 수술을 전문으로 하는 비상장 회사입니다. 이 인수로 Stryker의 신경 기술 분야에서의 입지가 강화되며, 특히 종양 및 뇌졸중 치료에서의 역할이 강조됩니다. ICH는 가장 치명적인 뇌졸중 형태로, 전 세계적으로 연간 340만명 이상에게 영향을 미치며, 30일 사망률은 40-50%입니다.
NICO의 BrainPath® 및 Myriad® 제품은 표준 의학적 관리에 비해 ICH 치료에서 개선된 기능적 결과를 제공합니다. Stryker의 MedSurg 및 Neurotechnology 그룹 사장인 Andy Pierce는 이번 전략적 추가가 회사를 차별화된 최소 침습적 접근법을 제공할 수 있도록 하여 전 세계적으로 환자들의 삶을 개선하고 의미 있는 성과를 이끌어낼 것이라고 밝혔습니다.
Stryker (NYSE: SYK) a terminé l'acquisition de NICO, une entreprise privée spécialisée dans la chirurgie peu invasive pour les tumeurs et les procédures d'hémorragie intracérébrale (ICH). Cette acquisition renforce la position de Stryker dans la neurotechnologie, en particulier dans les soins aux tumeurs et les AVC. L'ICH, la forme d'AVC la plus mortelle, touche plus de 3,4 millions de personnes par an dans le monde, avec un taux de mortalité de 40 à 50 % dans les 30 jours.
Les produits BrainPath® et Myriad® de NICO offrent de meilleurs résultats fonctionnels pour le traitement de l'ICH par rapport à la gestion médicale standard. Andy Pierce, président du groupe MedSurg et Neurotechnologie chez Stryker, a déclaré que cet ajout stratégique permettra à l'entreprise d'offrir des approches différenciées et peu invasives pour obtenir des résultats significatifs et améliorer la vie des patients à l'échelle mondiale.
Stryker (NYSE: SYK) hat die Übernahme von NICO abgeschlossen, einem privat geführten Unternehmen, das sich auf minimalinvasive Chirurgie für Tumor- und intrazerebrale Blutung (ICH)-Verfahren spezialisiert hat. Diese Übernahme stärkt die Position von Stryker im Bereich Neurotechnologie, insbesondere in der Tumor- und Schlaganfallversorgung. ICH, die tödlichste Form eines Schlaganfalls, betrifft jährlich über 3,4 Millionen Menschen weltweit, mit einer Sterblichkeitsrate von 40-50% innerhalb von 30 Tagen.
Die Produkte BrainPath® und Myriad® von NICO bieten im Vergleich zur Standardmedizin verbesserte funktionale Ergebnisse bei der Behandlung von ICH. Andy Pierce, Präsident der MedSurg- und Neurotechnologie-Gruppe bei Stryker, erklärte, dass diese strategische Ergänzung es dem Unternehmen ermöglichen wird, differenzierte und minimalinvasive Ansätze zu liefern, um bedeutende Ergebnisse zu erzielen und das Leben der Patienten weltweit zu verbessern.
- Acquisition expands Stryker's portfolio in tumor resection and ICH treatment
- NICO's products offer improved functional outcomes for ICH treatment
- Strengthens Stryker's position in the growing neurotechnology market
- Addresses a significant medical need with 3.4 million ICH cases annually
- None.
Stryker's acquisition of NICO is a strategic move to strengthen its position in the neurotechnology market. This expansion into minimally invasive solutions for brain tumor removal and stroke care aligns with the growing demand for advanced medical technologies in an aging population.
The deal targets the intracerebral hemorrhage (ICH) treatment market, which affects over
Investors should monitor how quickly Stryker can integrate NICO's products and leverage its existing distribution channels to accelerate market penetration. The success of this acquisition could drive Stryker's stock performance in the medium to long term, especially if clinical outcomes demonstrate superiority over current standard care.
The acquisition of NICO significantly enhances Stryker's capabilities in addressing intracerebral hemorrhage (ICH), a critical area with high unmet medical need. NICO's BrainPath® and Myriad® products offer a paradigm shift in ICH treatment, potentially improving patient outcomes compared to current medical management.
With ICH's
Key factors to watch include:
- Real-world data on functional outcomes using NICO's technology
- Potential expansion of indications for minimally invasive neurosurgery
- Integration of NICO's approach with Stryker's existing neurotechnology solutions
Stryker's acquisition of NICO is a strategic play in the growing neurotechnology market. With the global neurosurgery devices market projected to reach
The focus on minimally invasive solutions aligns with broader healthcare trends towards less invasive procedures, shorter hospital stays and improved patient outcomes. NICO's technology addresses a critical gap in stroke care, particularly for ICH, which has seen innovation in treatment approaches.
Key market dynamics to consider:
- Aging global population increasing demand for neurosurgical interventions
- Growing preference for minimally invasive procedures among patients and healthcare providers
- Potential for expanded reimbursement as evidence of improved outcomes accumulates
ICH, or bleeding in the brain caused by a ruptured blood vessel, is the deadliest form of stroke, affecting over 3.4 million people annually around the world, with rising rates due to an aging population.1,2 ICH has high morbidity and a 30-day mortality rate ranging from 40
"The acquisition of NICO Corporation expands Stryker's portfolio of solutions for tumor resection and the treatment of intracerebral hemorrhage, the deadliest form of stroke," said Andy Pierce, group president, MedSurg and Neurotechnology, Stryker. "As a global leader in neurosurgical access and removal tools, this strategic addition enables us to deliver differentiated, minimally invasive approaches that will drive meaningful outcomes and improve the lives of patients worldwide."
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.
Media contact
Beth Sizemore
Stryker
Senior Director, Communications
beth.sizemore@stryker.com
References
1 Sun T, Yuan Y, Wu K, et al. (2023) Trends and patterns in the global burden of intracerebral hemorrhage: a comprehensive analysis from 1990 to 2019. Frontiers in Neurology. 14:1241158.
2 Katan M, Luft A. Global Burden of Stroke. Semin Neurol. 2018 Apr;38(2):208-211. doi: 10.1055/s-0038-1649503. Epub 2018 May 23. PMID: 29791947.
3 Woo, D, Comeau ME, Venema SU, et al. (2022). Risk Factors Associated With Mortality and Neurologic Disability After Intracerebral Hemorrhage in a Racially and Ethnically Diverse Cohort. JAMA Netw Open. 5(3):e221103
4 Pradilla G., Ratcliff, JJ, , Hall, AJ, et al. (2024). Trial of Early Minimally Invasive Removal of Intracerebral Hemorrhage. New England Journal of Medicine. 390(14), 1277-1289.
5 Greenberg, SM, Ziai WC, Cordonnier C., et al. (2022) 2022 Guideline for the Management of Patients with Spontaneous Intracerebral Hemorrhage: A Guideline from the American Heart Association/American Stroke Association. Stroke. 53(7), e282-e361.
View original content to download multimedia:https://www.prnewswire.com/news-releases/stryker-completes-acquisition-of-nico-corporation-expanding-minimally-invasive-solutions-for-brain-tumor-removal-and-stroke-care-302253611.html
SOURCE Stryker
FAQ
What company did Stryker (SYK) acquire on September 20, 2024?
How does the NICO acquisition benefit Stryker's (SYK) neurotechnology portfolio?
What are the key products from NICO that Stryker (SYK) has acquired?
How prevalent is intracerebral hemorrhage (ICH) according to Stryker's (SYK) press release?
